Skip to content

Cancer Genetics & Molecular Oncology

Clinician referral required

ABL1 Kinase Domain Mutations (TKI Resistance)

Looks for ABL1 mutations linked to resistance to tyrosine kinase inhibitor treatment in BCR-ABL positive leukaemia.

Test code:

  • Sample

    Blood

  • Method

    Next Generation Sequencing (NGS)

  • Turnaround

    21 days

About this test

Looks for ABL1 mutations linked to resistance to tyrosine kinase inhibitor treatment in BCR-ABL positive leukaemia.

Screens forChronic myeloid leukaemia

Yes, a doctor's referral is required for this test.

No special preparation is usually required; confirm specimen-specific instructions with the laboratory.

Samples can be collected at the GeneLabs X Centre in Kotte or at any of our designated sample collection centres.

The results indicate whether mutations are detected in the ABL tyrosine kinase (TK) domain. Discuss the results with your doctor before making any decisions.

Need help?

Not sure this is the right test?

Our team can help you or your clinician find the right pathway.